I Squared Capital Names Three New Partners
The Management Committee of I Squared Capital is pleased to announce the appointment of Andreas Moon as Partner, Chenhua Shen as Fund Partner, and Enrico Del Prete as Fund Partner, bringing the total number of partners at I Squared Capital to eleven. “In our tenth anniversary year, I am so proud to be part of this extraordinary group whose combined talents have contributed so much to the success of the firm,” said Sadek Wahba, Chairman and Managing Partner of I Squared Capital. “Our new partners have helped build I Squared Capital into a vibrant global platform with over $34 billion of assets under management and a diverse portfolio of infrastructure assets around the world. They have demonstrated the talent and innovation necessary to execute on our long-term strategy and help lead the firm on its next phase of growth.”
The firm continues to grow rapidly and, with the recent closing of ISQ Global Infrastructure Fund III at $15 billion, I Squared now has over $34 billion in assets under management. With this growth comes the need for additional resources across the firm. Over the past six months, 19 professionals have joined across various groups including ten on the investment team and nine in other functions. Over the course of the coming period, we look to add significant resources, including investment professionals in the U.S., Latin America, Europe, and Asia, as well as the Credit and InfraTech platforms, some of whom will be announced shortly.
I Squared Capital is an independent global infrastructure investment manager focusing on utilities, digital infrastructure, energy, transport and social infrastructure in North America, Europe, Latin America, and Asia. Headquartered in Miami, the firm also has offices in Hong Kong, London, New Delhi, Singapore, and Taipei.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220411005303/en/
Contact information
Andreas Moon, Partner and Head of Investor Relations
+1 (786) 693-5739 | andreas.moon@isquaredcapital.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ireland Unveils Seven New Halloween Experiences30.10.2025 16:00:00 EET | Press release
With seven brand-new Halloween hubs or experiences launching across the island this month, Ireland has truly become the ultimate destination to celebrate Halloween in 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022209535/en/ Derry Halloween Festival, County Derry~Londonderry Ireland’s Halloween Season Rooted in the ancient Celtic festival of Samhain, Halloween originated in Ireland more than 2,000 years ago and, this year, the island of Ireland is expanding its celebration like never before. With over 340 events planned across the island to celebrate this year, Halloween in Ireland is fast becoming a bucket-list travel experience. Seven new Halloween hubs join existing flagship events across the island of Ireland including the Púca Festival in County Meath and Derry Halloween in Derry-Londonderry which together welcomed over 169,000 visitors last year. The seven new hubs are inviting visitors to come and explore
Staloral ® Birch Phase III Study Successfully Meets Primary Endpoint, Demonstrating Efficacy in Children and Adolescents30.10.2025 15:56:00 EET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, announced today that its Phase IIIb clinical study (YOBI, YOung patients and BIrch allergy), designed to confirm the safety and efficacy of Staloral® Birch in children and adolescents with birch pollen-induced allergic rhino-conjunctivitis (ARC), with or without asthma, has successfully achieved its primary endpoint. The trial enrolled 553 children aged 5 -17 years with moderate to severe birch pollen-induced ARC, with or without asthma, across 64 sites in 12 European countries and assessed the efficacy and safety of Staloral® birch 300IR daily maintenance dose administered pre-and co-seasonally over two consecutive birch pollen seasons. The YOBI study successfully met its primary endpoint, demonstrating the efficacy of Staloral® Birch in a paediatric population (5-17) with a 41% improvement in the ARC total combined score during the second pollen season compared to placebo. These results were highly statistically significant
Andersen Consulting Enhances Its Platform Through Collaboration With threon30.10.2025 15:30:00 EET | Press release
Andersen Consulting deepens its business transformation and digital transformation capabilities through a Collaboration Agreement with threon, a Belgium-based consultancy known for delivering pragmatic, end-to-end strategy execution support. For more than 20 years, threon has been a trusted advisor for organizations looking to turn big ideas into delivering true business impact. The firm brings together their expertise in strategic portfolio management, digital transformation, and executive training to help leaders move from vision to execution. Threon’s unique approach blends project delivery, workforce development, and smart software solutions, empowering teams to deliver faster, scale with confidence, and achieve lasting results. CEO of threon Tom Dedecker said, “We bring focus and peace to organizations, enabling faster decision-making and sustainable transformation rooted in their unique identity.” Eric Noerdinger, managing director of threon added, “Our goal is to embed change su
Bending Spoons Raises $710M for Continued Investment and Growth30.10.2025 15:00:00 EET | Press release
Bending Spoons, one of Europe’s leading technology companies, today announced it has raised $710 million in equity at a pre-money valuation of $11 billion. The round was led by accounts advised by T. Rowe Price Investment Management, Inc., with participation from Baillie Gifford, Cox Enterprises, Durable Capital Partners, Fidelity Management & Research Company, Foxhaven Asset Management, and Radcliff, among others. Goldman Sachs International acted as sole placement agent and Clifford Chance served as legal advisor to the transaction. Notarial advisory services were provided by ZNR Notai. “This moment is a validation of a decade’s worth of work and it serves as an important recognition of what we’ve accomplished at Bending Spoons so far. We remain early in our journey and have ambitious plans for continued investment and growth,” shares Luca Ferrari, co-founder and CEO of Bending Spoons. “We’re proud to bring on some of the world’s finest investors who believe in our approach to value
Debiopharm Forges AI-powered Alliance With NetTargets to Pioneer Dual-payload ADCs Against Drug-resistant Cancers30.10.2025 15:00:00 EET | Press release
Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based, biopharmaceutical company dedicated to developing innovative therapies that respond to high unmet medical needs, today announced a strategic research collaboration with NetTargets (www.net-targets.com), a South Korean biotech company specializing in AI-enhanced systems biology for drug discovery, to rationally design and advance the discovery of novel, synergistic drug combinations for Debiopharm’s next-generation Antibody-Drug Conjugates (ADCs). This alliance unites NetTargets' sophisticated artificial intelligence (AI) platform with Debiopharm's proprietary MLINKtechnology to create a new paradigm in cancer treatment, aiming to deliver a decisive, dual-action blow against treatment-resistant tumors. This collaboration achieves this multi-pronged strategy by uniting two cutting-edge technologies: NetTargets' AI-Powered Discovery Engine and Debiopharm's MLINK Duo Technology. NetTargets' proprietary AI platform integrates
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom